Silmitasertib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Silmitasertib" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

7doi.org

2^nd place

2who.int

195^th place

302^nd place

1americanlifefund.com

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1biospectrumasia.com

low place

americanlifefund.com

Lacey E (31 October 2022). "Owner". American Life Fund. Retrieved 19 December 2022.

biospectrumasia.com

"Senhwa Biosciences, NIH to co-develop COVID-19 drug". BioSpectrum. 27 April 2020.

clinicaltrials.gov

Clinical trial number NCT03904862 for "PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma" at ClinicalTrials.gov

doi.org

Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, et al. (September 2018). "Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma". Science Signaling. 11 (547): eaau5147. doi:10.1126/scisignal.aau5147. PMC 6475502. PMID 30206138.
Gowda C, Sachdev M, Muthusami S, Kapadia M, Petrovic-Dovat L, Hartman M, et al. (2017). "Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies". Current Pharmaceutical Design. 23 (1): 95–107. doi:10.2174/1381612822666161006154311. PMID 27719640.
No authors listed (2017). "CX-4945 granted orphan drug designation". Oncology Times. 39 (5): 23. doi:10.1097/01.COT.0000514203.35081.69.
Chon HJ, Bae KJ, Lee Y, Kim J (2015). "The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies". Frontiers in Pharmacology. 6: 70. doi:10.3389/fphar.2015.00070. PMC 4379896. PMID 25873900.
Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, et al. (December 2010). "CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy". Cancer Research. 70 (24): 10288–10298. doi:10.1158/0008-5472.CAN-10-1893. PMID 21159648.
Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. (August 2020). "The Global Phosphorylation Landscape of SARS-CoV-2 Infection". Cell. 182 (3): 685–712.e19. doi:10.1016/j.cell.2020.06.034. PMC 7321036. PMID 32645325.
Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, et al. (January 2011). "Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer". Journal of Medicinal Chemistry. 54 (2): 635–654. doi:10.1021/jm101251q. PMID 21174434.

nih.gov

pubmed.ncbi.nlm.nih.gov

Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, et al. (September 2018). "Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma". Science Signaling. 11 (547): eaau5147. doi:10.1126/scisignal.aau5147. PMC 6475502. PMID 30206138.
Gowda C, Sachdev M, Muthusami S, Kapadia M, Petrovic-Dovat L, Hartman M, et al. (2017). "Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies". Current Pharmaceutical Design. 23 (1): 95–107. doi:10.2174/1381612822666161006154311. PMID 27719640.
Chon HJ, Bae KJ, Lee Y, Kim J (2015). "The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies". Frontiers in Pharmacology. 6: 70. doi:10.3389/fphar.2015.00070. PMC 4379896. PMID 25873900.
Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, et al. (December 2010). "CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy". Cancer Research. 70 (24): 10288–10298. doi:10.1158/0008-5472.CAN-10-1893. PMID 21159648.
Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. (August 2020). "The Global Phosphorylation Landscape of SARS-CoV-2 Infection". Cell. 182 (3): 685–712.e19. doi:10.1016/j.cell.2020.06.034. PMC 7321036. PMID 32645325.
Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, et al. (January 2011). "Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer". Journal of Medicinal Chemistry. 54 (2): 635–654. doi:10.1021/jm101251q. PMID 21174434.

ncbi.nlm.nih.gov

Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, et al. (September 2018). "Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma". Science Signaling. 11 (547): eaau5147. doi:10.1126/scisignal.aau5147. PMC 6475502. PMID 30206138.
Chon HJ, Bae KJ, Lee Y, Kim J (2015). "The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies". Frontiers in Pharmacology. 6: 70. doi:10.3389/fphar.2015.00070. PMC 4379896. PMID 25873900.
Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. (August 2020). "The Global Phosphorylation Landscape of SARS-CoV-2 Infection". Cell. 182 (3): 685–712.e19. doi:10.1016/j.cell.2020.06.034. PMC 7321036. PMID 32645325.

who.int

apps.who.int

World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 103" (PDF). WHO Drug Information. 24 (2): 166–167.

who.int

World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 66" (PDF). WHO Drug Information. 25 (3): 329.